MedTrace Logo

A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors

NCT04343859 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2023-11-09

No results posted yet for this study

Summary

Phase I study of IMMH-010 in patients with advanced malignant solid tumors

Conditions

  • Malignant Neoplasms

Interventions

DRUG

IMMH-010

After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.

Sponsors & Collaborators

  • Tianjin Chasesun Pharmaceutical Co., LTD

    lead INDUSTRY

Principal Investigators

  • Yilong Wu · Guangdong Provincial People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-14
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04343859 on ClinicalTrials.gov